Dry powder inhalation:technical and physiological aspects, prescribing and use by Koning, Johannes Petrus de
  
 University of Groningen
Dry powder inhalation
Koning, Johannes Petrus de
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2001
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Koning, J. P. D. (2001). Dry powder inhalation: technical and physiological aspects, prescribing and use.
s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
















J.P. de Koningu, M.R. Visseru, G.A. Oelenu, A.H. de Boeru, Th.W. van der Mark&,
P.M.J. Coenegracht#, Th.F.J. Tromp,, H.W. Frijlinku
 
Groningen University Institute for Drug Exploration (GUIDE), Department of Pharmacy,
uPharmaceutical Technology and Biopharmacy, #Chemometrics, ,Pharmacy Practice, University of Groningen,
&Department of Pulmonology, University Hospital Groningen, The Netherlands
$EVWUDFW
Several in vitro as well as in vivo studies have emphasised the importance of generating a
particular peak inspiratory flow (PIF) when using a dry powder inhaler (DPI). But also other
parameters, such as the flow increase rate (FIR20-80%), may affect the performance of this type
of inhaler devices. In the present study both the effect of PIF and the FIR20-80% on the fine
particle output from four corticosteroid DPI’s was investigated. For the in vitro evaluation of
the inhaler performance a four stage cascade impactor method is used, with a controllable
inspiratory flow profile. The range of PIF and the FIR20-80% values were based on previous in
vivo experiments, having physiological relevance. From the four investigated devices, the fine
particle output from the Turbuhaler is the most sensitive to PIF and FIR20-80%. However, this
device also had the highest fine particle output; more than 50% of the nominal dose at
60 l·min-1 and a FIR20-80% of 7.5 l·s-2. The fine particle output for the Diskhaler, Diskus and
Cyclohaler also vary with PIF and the FIR20-80%, although variations are relatively small. The
maximum fine particle output for the Diskhaler is 23%, for the Diskus 33% and for the
Cyclohaler 29% of the nominal dose. For all four tested inhalers it should be recommended to
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 ,QWURGXFWLRQ
The cornerstone of modern asthma treatment is inhalation therapy with corticosteroids. The
amount of deposited fine particles in the target area, the lower respiratory tract, is important.
Little information is available on the fine particle output of the inhaled dose of corticosteroids
from different inhalers. Dry powder inhalers are described as breath-actuated drug delivery
systems, which are widely used in the treatment of pulmonary diseases. Available DPI’s have
different designs, which amongst other things results in different resistances to airflow during
inhalation. Therefore, with the same inhalation performance different inhalation profiles have
been obtained through the different inhaler devices (chapter 2, chapter 3, and chapter 4). Fine
particle output of the device depends on the generated flow profile, the inhaler design, and the
used powder formulation. It may therefore be expected that for each inhaler device in
combination with a particular drug formulation an optimal flow profile exists at which the
highest amount of fine particles is generated.
DPI’s can be categorised in two major groups, single dose and multi-dose inhalers. The multi-
dose inhalers are divided in two different types of design: the reservoir systems and the
multiple unit-dose inhalers. An example for the reservoir system is Turbuhaler (figure 6.1). In
this type of inhaler, the powder formulation is stored in a container from which a single dose
is measured volumetrically with a special dose-metering unit. Accurate dose metering for this
type of inhaler requires careful manipulation of the device at the moment of patient use. In the
multiple unit-dose inhaler, single doses are filled by the manufacturer into suitable dose
compartments, such as blisters. Examples are Diskhaler (figure 6.1), having the blisters on a
disk (Rotadisk), and Diskus (figure 6.1) with the blisters on a long strip. Before inhalation, a
single blister is either perforated or the cover foil is peeled off the blister foil in order to gain
access to one single dose.










usually capsules, that have to be placed into the inhaler by the patient. Capsule cap and body
must be separated before inhalation or the capsule has to be pierced at both ends, as for the
Cyclocaps for Cyclohaler (figure 6.1).
Turbuhaler Diskhaler Diskus Cyclohaler
(AstraZeneca) (GlaxoWellcome) (GlaxoWellcome) (Pharbita)
Figure 6.1: Dry powder inhaler devices used for in vitro deposition study.
For the many available DPI’s, two different types of powder formulations are currently
applied. So-called spherical pellets are used in the Turbuhaler. In this type of formulation, the
micronised drug particles are agglomerated into much larger units without binder agent and
subsequently spheronised into a free flowing powder. The formulation does not contain
coarser carrier crystals. Pellets can disintegrate rather completely during inhalation into much
smaller agglomerates or even primary particles that have the required size range for deep
penetration into the respiratory tract. The Rotadisk for Diskhaler, the blisters in Diskus and
the Cyclocaps for Cyclohaler are filled with adhesive mixtures. This type of formulation
consists of relatively large carrier crystals, mostly α-lactose monohydrate, carrying the
micronised drug particles distributed over their surface. During inhalation, the drug particles
have to be released from the carrier crystals to enter the lower respiratory tract. The fraction
of drug not detached may cause local side effects, like candidiasis, in the upper respiratory
tract (mouth and throat) where the larger particles are deposited.
For DPI’s, the principle of operation is to use the patients generated inspiratory flow as
energy source. After activation of the dose system, the onset of the patient’s inspiratory flow
starts entrainment of the powder from the dose system, and the disintegration of the powder
formulation. Delivery and deposition of fine drug particles into the respiratory tract will
follow. The generated inspiratory flow curve is one of the major determinants for DPI
performance(1). The inspiratory flow as generated by different patients is variable and depends
on the patient's inhalation performances. As shown in chapter 2, the shape of the inspiratory


































inspiratory flow rate (PIF); acceleration in inspiratory flow rate, the so-called flow increase
rate (FIR20-80%); total inhalation time; time needed to reach PIF (time to PIF); the inspiratory
volume to reach PIF; and the time during which a certain flow through the inhaler can be
maintained, the so-called dwell time (DT80%).
PIF is often the only flow parameter that is controlled adequately when the in vitro
performance of DPI’s is determined. For inhalers with large volume of drug and carrier
powder, the total inhalation time is important. On the other hand, recent studies(2-4) show that
also other parameters of the inspiratory flow curve, such as the flow increase rate (FIR), may
be important for the evaluation of inhaler performance.
In each of the studies FIR is differently defined. Everard et al.(4) defined FIR (s-1) as flow
after 150 ml of inhaled volume. Burnell et al.(3) defined FIR (l·min-1·s-1) as flow acceleration
during dose emission. De Boer et al.(2) defined FIR (l·s-2) as flow increase rate from 30 to
40 l·min-1. In the presented study a more general applicable definition of flow increase rate is
used. The flow increase rate (l·s-2) is defined as the mean acceleration in airflow from 20% to
80% of the peak inspiratory flow (FIR20-80%). The change in slope at the start of inhalation as
well as near PIF is large and may therefore dominate average FIR values from start to PIF. In
the definition of FIR20-80% these parts of the curve are excluded. This definition allows a
reproducible measurement of FIR in a broad range of resistances to airflow.
In the present study the effects of both the PIF and the FIR20-80% on the in vitro drug
deposition from four corticosteroid DPI’s (figure 6.1) were investigated. A range of PIF-
values as well as FIR20-80%-values was defined, based on the inspiratory flow curves that were
measured in an earlier study (chapter 3 and chapter 4) in healthy subjects, asthmatics and
COPD patients. For the in vitro evaluation of the inhaler performance a four stage cascade
impactor was used. The impactor classifies the drug particles from the inhaler into size
fractions that are relevant to lung deposition. The fractions retained from the 3rd and 4th
impactor stages are considered to be the fine particles that are likely to enter the target area in
the lower respiratory tract(5).
 0DWHULDOVDQG0HWKRGV
For this study, three types of multi-dose DPI’s and one single-dose DPI with corticosteroid
formulations were used. The inhalers were Pulmicort Turbuhaler, containing 200 doses of 200
µg budesonide per nominal dose; Flixotide Diskhaler, with Flixotide Rotadisks (4-doses),
containing 250 µg fluticasone propionate per nominal dose; Flixotide Diskus, containing 60
doses of 250 µg fluticasone propionate; and the Cyclohaler, with budesonide Cyclocaps,
containing 200 µg budesonide per nominal dose. To complete the whole study, several
devices of the same inhaler type were necessary. In order to exclude batch variation, the
different inhalers of the same type were derived from the same batch (first listed batch










examination of batch to batch variation, and the influence of drug load on the carrier crystals.
All inhalers were provided by a community pharmacy.
 ,QKDOHUVSHFLILFUHVLVWDQFHWRDLUIORZ
Inhaler specific resistance to airflow was calculated as the slope in the linear relationship
between the square root of pressure drops and flow rate(6-8). The experimental set-up (figure
6.2) consists of a thermal mass flow meter (Brooks, The Netherlands, model 5863S (range up
to 2.5 ln·s-1)), a flow controller (Festo, Germany, Drossel-Rückschlagventil type 3720 GR-½)
and a coupling flange for the inhaler device. Pressure drop across the inhaler device was
recorded with a differential pressure gauge (HBM, Germany, type PD1 (range 100 kPa))
connected to a computer. Inspiratory flow was generated by using partial vacuum, provided
by a vacuum pump (Leybold, USA, model Sogevac SV 40). Inhaler specific resistance to
airflow was used in the cascade impactor analysis to calculate the volumetric flow rate
through the inhaler device from the recorded pressure drop.
M F M
dP
Mass Flow MeterFlow control ler
Differential
pressure gauge
P u m pInhaler
Figure 6.2: Experimental set-up for the measurement of relationship between pressure drop
and flow rate for the different dry powder inhalers.
 &DVFDGHLPSDFWRUDQDO\VLV
Cascade impactor analysis with the selected inhaler types was performed at different flow
increase rates and different flow rates. To obtain flow profiles, with the desired flow increase
rates and flow rates, special experimental set-ups were used (figure 6.3 and figure 6.4). The
pressure against time profiles were recorded with a computer. From the recordings, the PIF
and FIR20-80% values were calculated.
For the measurement of dry powder inhaler performance, two identical four-stage cascade
impactors (Lenz Labor Instruments, The Netherlands, Fisons type) with dry bent inlet tubes
were used for the flow rates up to 60 l·min-1. For flow rates above 60 l·min-1 a cascade
impactor with a modified 4th stage was used(9). The modified 4th stage had a lower resistance
to airflow and, therefore, analyses with higher flow rates were possible. The size distribution
of the fines derived from the 3rd and 4th stages of both impactors varied with the flow rate,


































stage depends on the flow rate. Fine particle losses as the result of incomplete collection
efficiency can not be assessed accurately, although it is known that these losses are less
substantial for the modified impactor than for the standard device. The cut-off diameters of
the 2nd stage with 50% collection efficiency can be calculated as function of particle density
and the inspiratory flow rate. Within the range of applied flow rates, the theoretical upper
class limit of the fine particle fraction decreases from 12.4 µm at 30 l·min-1 to 7.6 µm at
80 l·min-1 for spherical pellets with a true density of 1.5 g·cm3(10). This implies that the fine
particle fraction is considerably narrower at 80 l·min-1 than at 30 l·min-1. For this reason, the
obtained fine particle mass fractions, also referred to as fine particle output, derived from the
3rd and 4th stages are not expressed in terms of aerodynamic particle diameter, but they have
been calculated as percentage of the nominal dose, the so–called label claim. The mass
fractions collected on the 3rd and 4th stage are considered to be most relevant for deposition in
the lower respiratory tract(5).
For the cascade impactor analysis, a coupling flange with exchangeable rubber seal was
mounted on the inlet tube for holding the inhalers during testing (figure 6.3). From this
coupling flange, a tube connection was made to a differential pressure gauge. The required
flow rate through the dry powder inhalers during cascade impactor analysis was obtained by
adjusting the corresponding pressure drops across the device with a flow controller. The
inspiration time was controlled with a time controlled solenoid valve (Honeywell,














Figure 6.3: Experimental set-up for standard cascade impactor analysis
(FIR20-80% = 2.3 l·s-2). Reduced flow increase rate (FIR20-80% = 1.2 l·s-2) was obtained by
introducing a buffer volume.
For the standard cascade impactor analysis, the FIR20-80% is approximately 2.3 l·s-2. Reduced
FIR20-80% is obtained by introducing a volume buffer of 1 litre in the system (figure 6.3). The










cascade impactor analysis. Higher FIR20-80% is obtained by introducing a small pre-inhalation
partial vacuum in the cascade impactor before the start of the actual inhalation (figure 6.4).
That way the initial pressure drop across the DPI increased. The FIR20-80% was accurately
controlled with the speed adjustable three-way valve and the amount of partial vacuum in the
system (appendix, figure 6.10). For the cascade impactor analysis with increased FIR20-80%,
the inhalers were placed in a specially designed closed inhaler adapter, with exchangeable
inhaler housings for the different types of DPI’s (appendix, figure 6.11). In the pre-inhalation
situation, the partial vacuum in the cascade impactor system was adjusted with flow controller
4 (figure 6.4). To start the inhalation through the cascade impactor, the speed adjustable three-
way valve changed direction by activating the time controlled valves. Both valves were
synchronised with the same timer. The speed of the three-way valve was controlled by the
flow rate of pressurised air, which was adjusted by flow controller 1. With the speed of
changing the flow direction in the three-way valve as well as the amount of pre-inhalation
partial vacuum in system the FIR20-80% rate could be controlled. Flow controllers 3 and 5 were
used to adjust the PIF through the inhaler system.
Flow control ler
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Figure 6.4: Experimental set-up for cascade impactor analysis for
higher flow increase rates. (Pre-inhalation situation)
For each cascade impactor analysis, 2000 µg of active compound (based on nominal dose)
was inhaled in the cascade impactor. Therefore, each cascade impactor result is the mean of a
series of ten successive inhalations for the Turbuhaler and Cyclohaler, both with 200 µg per
nominal dose. For the Diskhaler and the Diskus, both with 250 µg per nominal dose, eight
successive inhalations were used per cascade impactor analysis. For the Turbuhaler,
containing 200 doses, only the doses 10-180 from each device was used in order to avoid


































Fractions deposited in the cascade impactor and accumulated in the inhaler devices, were
dissolved in pure ethanol. For the Diskhaler, blister residues were also analysed.
Accumulation and waste of dose in the inhaler device is difficult to measure. Especially in the
multi-dose inhalers as Turbuhaler and Diskus, because in both inhalers the dose system
cannot be rinsed without affecting the remaining doses. For the Turbuhaler it is possible to
measure the mouthpiece accumulation by simple reassembling and rinsing of the mouthpiece.
For the Diskhaler, waste in the Rotadisk, and mouthpiece accumulation can be measured by
rinsing the Rotadisk and the mouthpiece after the admission of all inhalations into the cascade
impactor. For the Cyclohaler it is possible to measure the mouthpiece accumulation by rinsing
the inhaler, but with our measurement method it is not possible to measure the remaining drug
in the Cyclocaps. All drug solutions of fractions collected from the Diskhaler, Diskus and
Cyclohaler were treated in a centrifuge (3000 rpm. for 5 min.) in order to precipitate the
lactose carrier crystals. Analysis was performed by UV absorption at 243.7 nm for
budesonide, and 236.6 nm for fluticasone propionate, using a PU 8720 UV/VIS
Spectrophotometer (Philips, The Netherlands).
 &DUULHUUHVLGXHDQDO\VLV
After the disintegration of an adhesive mixture, a fraction of the active material will still be
attached to the carrier crystals, the so-called carrier residue. The carrier residue as a function
of drug load on the carrier crystals can be measured with a specially designed test inhaler
device(11). The test inhaler has a cyclone based disintegration principle that can withhold
larger carrier particles. The withheld carrier particles were analysed upon adhering drug
particles after inhalation, the so-called carrier residue. The percentage carrier residue is the
active compound still attached to the carrier particles in the cyclone chamber at the end of the
inhalation cycle expressed as the percentage of the nominal dose. For each carrier residue
analysis, 2000 µg of active compound (based on nominal dose) was inhaled. For the
comparison of the powder formulation from the Rotadisk and the Diskus, the amount of
carrier crystals at each inhalation was kept constant. Therefore, eight inhalations each with the
content of one blister from a Rotadisk were carried out (25 mg lactose carrier crystals). For
the Diskus, four inhalations each with the contents of two blisters were carried out (2x12.5 mg
lactose carrier crystals). After each inhalation, the carrier crystals were retained from the
cyclone chamber. The total carrier residue was collected and analysed. The inhalation












The inhaler specific resistances to airflow are presented in table 6.1. The highest resistance to
airflow is found for the Turbuhaler, while the lowest resistance to airflow is found for the
Cyclohaler.
Table 6.1: Characteristics of used inhaler devices
Inhaler device Resistance to airflow Batch numbers
Turbuhaler Pulmicort 200
(AstraZeneca) 81.7  Pa
0.5
·s· l-1 03-2000 98C24-A ZC 991
Diskhaler Flixotide 250
(GlaxoWellcome) 52.5  Pa
0.5
·s· l-1
Diskhaler: 98 06 15
Rotadisk 250: 98 07 02/1 Jul-00
Rotadisk 250: 99G 21/2 Jul-2001
Rotadisk 500: 99H 25/2 Aug-2001
Diskus Flixotide 250
(GlaxoWellcome) 50.1  Pa
0.5
·s· l-1 99C 28 B Sep-0099G 26 E Jan-01
Cyclohaler Budesonide 200
(Pharbita) 34.3  Pa
0.5
·s· l-1 Cyclohaler: 99-04Cyclocaps: 01 2001 2F 0170 98 A 06
 &DVFDGHLPSDFWRUDQDO\VLV
Typical flow rate against inhalation time curves for cascade impactor analyses at standard









































Figure 6.5: Typical flow rate against inhalation time curves for cascade impactor analysis
 at a FIR20-80% of 2.3 l·s-2 and at a higher FIR20-80% of 8 l·s-2.
In figure 6.6 and figure 6.7 the retained drug fractions from the cascade impactor analysis as
percentage of the nominal dose are given for the four investigated DPI’s. Figure 6.6 shows the


































length of the bars represents the total drug recoveries for the analyses. Figure 6.7 shows the
results of the comparable analyses at a higher flow increase rate. The total drug recovery is
relatively constant at increasing inspiratory flow rate and flow increase rate for the different
inhaler devices. However, the percentages collected from the different stages change. For the
Turbuhaler the fine particle output increases with increasing inspiratory flow rate (figure 6.6).
At higher FIR20-80% an identical trend is found (figure 6.7). Moreover, the fine particle output








120 Turbuhaler Diskhaler Diskus Cyclohaler



























30 40 50 60 70 40 60 8030 40 50 60 70 80 30 40 50 60 70
Figure 6.6: Amount of drug deposited on the four different impactor stages, inlet tube and
mouthpiece as a percentage of the nominal dose at different PIF's at a standard FIR20-80% of
2.3 l·s-2 for the Turbuhaler, Diskhaler, Diskus and Cyclohaler. For the Diskhaler, also the
remaining amount of drug in the Rotadisk was measured.
For the Diskhaler an increase in the 1st stage deposition is found at increasing flow rates. This
can be explained with a decreasing amount of drugs remaining in the Rotadisk and the
mouthpiece. The total amount of drug found on the 1st stage for the Diskhaler, Diskus and
Cyclohaler are relatively high compared to the Turbuhaler. This is a consequence of the
presence of large lactose carrier crystals in the drug formulation of the Diskhaler, Diskus and
Cyclohaler. Since, larger particles are deposited on the 1st stage of the cascade impactor, the
high amount of 1st stage deposition is considered to be the fraction of the drug that was not
released from the carrier particles.
The drug accumulation in the mouthpiece is different for all four types of DPI’s. Differences










Turbuhaler, the total mouthpiece was disconnected from the inhaler and analysed. For the
Diskhaler and the Cyclohaler, the mouthpiece was rinsed with ethanol. For the Diskus,
analysis of mouthpiece accumulation was difficult. With a brush the mouthpiece was cleaned
and the removed particles were analysed. The Turbuhaler has a construction in which the
mouthpiece is the major disintegration system of the inhaler. A relatively high number of drug
particles make contact with the inner walls of the mouthpiece. Since fine particles are
sensitive to accumulation due to Van der Waals forces and electrostatic charges, a relatively
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Figure 6.7: Amount of drug deposited on the four different impactor stages, inlet tube and
mouthpiece as a percentage of the nominal dose at different PIF's and a higher FIR20-80%
of 8 l·s-2 for the Turbuhaler, Diskhaler, Diskus and Cyclohaler. For the Diskhaler, also
the remained amount of drug in the Rotadisk was measured.
other inhalers, the mouthpiece is a less important design parameter for the disintegration of
the drug formulation. Additionally, the large carrier particles in the drug formulation may
sweep previously accumulated drug particles from the walls of the mouthpiece, which reduces
the mouthpiece deposition. Inlet tube and 1st stage deposition are a measure for the mouth and
throat deposition. Deposition of corticosteroids in the throat is responsible for local side
effects as dysphonia (hoarse voice), sore throat, and oropharyngeal candidiasis. Reduction of
drug deposition in this region might help to reduce these local side effects(12).
The total drug deposition on the 3rd and 4th stage of the cascade impactor is a measure for the
fine particle output from the DPI and represents the respirable fraction that can enter the lower


































both the FIR20-80% and the PIF through the inhaler is presented as contour plots in figure 6.8.
As demonstrated in the contour plots the fine particle output pattern (isofines) is different for
the four types of investigated DPI’s. For all four DPI’s a slight decrease in fine particle output
is found at flow rates above 60 l·min-1. This decrease is not expected and is considered to be
an artefact introduced by the cascade impactor method. At increasing flow rate, the collection
efficiency for the finest particles decreases.
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Figure 6.8: Contour plots for the relationship between PIF through the inhalers, the FIR20-80%
and the fine particle output as a percentage of the nominal dose, for the Turbuhaler,










The fine particle output from the Turbuhaler depends on both the PIF and the FIR20-80%. The
optimal fine particle output is found at a PIF near 60 l·min-1 and a FIR20-80% near 7.5 l·s-2. In
this area, a fine particle output above 50% of the nominal dose is found. For an optimal
inhaler performance of Turbuhaler it is therefore important that patients inhale forcefully and
deeply. This is also demonstrated in in vivo experiments in literature(13). As demonstrated in
chapter 3, the actual generated mean PIF, by volunteers and patients, through a resistance to
airflow (R4) comparable with that of the Turbuhaler, is about 70 l·min-1 and the mean
FIR20-80% is found at 7.6 l·s-2, which fits in the area of optimal fine particle output.
The fine particle output for the Diskhaler, Diskus, and Cyclohaler also depends on the PIF
through the inhaler, although variations are relatively small. Both the Diskus and the
Cyclohaler show dependence of the fine particle output to the FIR20-80%. The maximal fine
particle output is 23% for the Diskhaler, 33% for the Diskus and 29% for the Cyclohaler.
Based on the fact that the cut-off value change at increasing flow rate, as discussed in section
6.2.2, the fine particle output of all four inhaler devices might even have a greater dependence
on the PIF and the FIR20-80% than shown in figure 6.8.
The difference in fine particle output between the Diskhaler and the Diskus is remarkable,
because the Diskus is designed to be equal to the Diskhaler(14). Small differences in the design
of the disintegration systems in the Diskus and Diskhaler might result in an increased fine
particle output from the Diskus. However, the main difference between both DPI’s is the
powder formulation. The used powder formulation in both inhalers is an adhesive mixture of
relatively large α-lactose monohydrate crystals, carrying the micronised drug particles on
their surface. A single dose in the Rotadisk for the Diskhaler consists of
25 mg lactose carrier particles, whereas a dose for the Diskus consists of 12.5 mg lactose
carrier particles. The drug load on the surface of the lactose carrier particles is therefore about
1% for the Rotadisk in the Diskhaler, and about 2% for the Diskus. It is known that the
detachment of the drug particles from the lactose carrier crystals during inhalation may be
influenced by the drug load. It is also known that the drug-to-carrier interaction may vary
considerably from batch to batch for the same type of marketed lactose. Effect of drug load on
fine particle output was measured with a special designed cyclone type test inhaler device(11),
in which the large carrier particles are withdrawn in the inhaler, whereas only the fine
particles are emitted. The amount of not detached drug from the carrier, the so-called carrier
residue, was determined for the powder formulations of the Rotadisk, as well as the Diskus. In
the Rotadisk, a 38.7% carrier residue was found, and for the Diskus, with a higher drug load,
a 26.3% carrier residue was found. This difference in carrier residue is probably one of the
reasons of the difference in fine particle output between both inhalers. Rotadisk containing
500 µg fluticason propionate have also a drug load of 2%, which is comparable to the drug
load in the Diskus. Therefore, cascade impactor analyses with Rotadisk 500 are performed


































FIR20-80% 6 l·s-2, whereas a carrier residue of 16.3% was found. The carrier residue is
decreased, compared to the 250 µg Rotadisk. But the fine particle output is not increased to
the level as found for the Diskus, with the same drug load on the carrier crystals.
Additionally, cascade impactor analyses with the Diskus and the Diskhaler from another
batch are carried out. The results in figure 6.9 show different fine particle outputs for the two
batches of the Diskhaler and Diskus, respectively. The difference between the Diskhaler and
the Diskus is only 5% for the batches used for the additional experiments (figure 6.9),
compered to 10% for the batches used for figure 6.8. This confirms a batch to batch variation
in powder formulation. Since it is found that the fine particle output from the Diskus is higher
than for the Diskhaler, for both batches, it seems reasonable to assume that there also exits an
effect of inhaler design on fine particle output. The first stage deposition in figure 6.9 and the
obtained carrier residues are in good agreement. It shows that the fraction not detached
decreases with increasing drug load. However, a lower carrier residue does not guarantee a
higher fine particle output, as there may be a shift from 3rd and 4th stage deposition towards


































Diskus 250 (99G 26 E)
Diskhaler 250 (99G 21/2)
Diskhaler 500 (99H 25/2)
Diskhaler 250 (98 07 02/1)
Diskus 250 (99C 28 B)
Figure 6.9: Comparison of the amount of drug deposited on the four different impactor
stages, inlet tube, mouthpiece and Rotadisk as a percentage of the nominal dose for two
batches of the Diskus 250 µg, two batches of the Diskhaler 250 µg and one batch of the
Diskhaler 500 µg. Cascade Impactor analysis was performed at 60 l·min-1
with a FIR20-80% of 6 l·s-2.
The results, as shown in figure 6.9, demonstrate a difference in fine particle output for the two
batches of Diskus, as well as for the Diskhaler. The difference in fine particle output between










result of this comparison between the Diskhaler and the Diskus it might be concluded that the
differences in fine particle output depend on the drug load on the carrier crystals, inhaler
design parameters, as well as batch to batch variation in powder formulation.
Fine particle output from the spherical pellet type inhaler, the Turbuhaler, is higher compared
to the adhesive mixture type inhalers as the Diskhaler, Diskus and Cyclohaler. These high
differences in fine particle output are mainly the result of different inhaler designs, and used
types of drug formulation. Break up forces, necessary for the disintegration of spherical
pellets are generally more effective than the removal forces acting on the fine particles
attached to the carrier crystals in adhesive mixtures.
It is shown that in vitro fine particle output depends on the shape of the inhalation curve,
especially for DPI’s, which are sensitive to the FIR20-80%. The results may also explain the
variation in fine particle output from the same type of DPI at the same PIF, as reported by
various authors(2, 8, 15-20), due to the use of different FIR20-80%. For a reliable evaluation of
deposition results for different DPI’s it is recommended to specify the inhalation curve not
only by PIF through the inhaler, but also by FIR20-80%, and inhalation time used. These
specifications should be given for in vitro as well as in vivo evaluation of DPI performance.
 &RQFOXVLRQV
Dry powder inhaler performance depends on type of drug formulation, the peak inspiratory
flow (PIF) as well as the flow increase rate (FIR20-80%). Therefore, DPI’s are better described
as breath-controlled inhaler devices instead of breath-actuated inhaler devices. In this study,
the inhaler performance of four corticosteroid DPI’s is investigated. The used ranges of PIF
and FIR20-80% values are based on attainable flow curves by healthy subjects, asthmatics and
COPD patients (chapter 3 and chapter 4). The fine particle output of the Turbuhaler is the
most sensitive to the PIF and the FIR20-80%. On the other hand, this type of inhaler also
exhibits the highest fine particle output. The fine particle output for the Diskhaler, Diskus and
Cyclohaler also varies with the PIF and the FIR20-80%, although variations are relative small.
Fine particle output from the different DPI’s depends on the inhaler design, as well as on the
type of drug formulation. Because the fine particle output from DPI’s depends on several
parameters of the inhalation curve, it is recommended to specify the inhalation curve more
extensively by PIF through the inhaler, FIR20-80%, and inhalation time used.
There are large differences in fine particle output between the investigated DPI’s. These
differences should be taken into account when changing the prescription of the inhaler device.
For the tested inhalers it should be recommended to patients to inhale forcefully and deeply
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Figure 6.10: Speed adjustable three-way valve for adjusting the flow increase rate during














Figure 6.11: Closed inhaler adapter for cascade impactor analysis at higher
flow increase rate. Two inner housings are designed, one (top) for the Diskus and the
other (bottom) for the Turbuhaler, Diskhaler or the Cyclohaler.
